Published in Int J Med Sci on November 04, 2016
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Cancer statistics, 2014. CA Cancer J Clin (2014) 72.81
Global cancer statistics, 2012. CA Cancer J Clin (2015) 53.52
Epithelial-mesenchymal transitions in development and disease. Cell (2009) 39.17
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (2007) 25.52
Cancer genome landscapes. Science (2013) 25.33
Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature (2007) 19.33
Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature (2010) 17.38
Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res (2004) 14.53
Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med (2008) 13.54
Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med (2013) 13.22
The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature (2010) 12.43
Circulating mutant DNA to assess tumor dynamics. Nat Med (2007) 10.33
EMT and dissemination precede pancreatic tumor formation. Cell (2012) 9.27
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A (2010) 7.77
Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer (2011) 7.69
Small (Sendai negative) branch-duct IPMNs: not harmless. Ann Surg (2012) 7.26
Tumor self-seeding by circulating cancer cells. Cell (2009) 6.66
Pancreatic adenocarcinoma. N Engl J Med (2014) 6.21
Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science (2014) 5.25
Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature (2015) 5.15
Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol (2014) 4.76
Circulating nucleic acids (CNAs) and cancer--a survey. Biochim Biophys Acta (2006) 4.60
Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res (2004) 4.48
Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell (2014) 4.44
Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett (2007) 4.35
WNT signaling pathway and stem cell signaling network. Clin Cancer Res (2007) 4.24
Whole genomes redefine the mutational landscape of pancreatic cancer. Nature (2015) 4.01
Tumour heterogeneity in the clinic. Nature (2013) 3.92
Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med (2010) 3.90
Circulating tumor cells: liquid biopsy of cancer. Clin Chem (2012) 3.87
Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol (2014) 3.70
Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell (2014) 3.68
Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol (2012) 3.51
Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin Cancer Res (2014) 3.50
RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science (2015) 3.48
RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature (2012) 3.40
Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol (2013) 3.34
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med (2015) 3.33
Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov (2012) 3.09
Decreased blood flow with increased metabolic activity: a novel sign of pancreatic tumor aggressiveness. Clin Cancer Res (2009) 3.01
Recent progress in pancreatic cancer. CA Cancer J Clin (2013) 2.88
Challenges in circulating tumour cell research. Nat Rev Cancer (2014) 2.81
Antibody therapeutics in cancer. Science (2013) 2.64
Biology and management of pancreatic cancer. Gut (2007) 2.53
Circulating tumor cell clusters in the peripheral blood of colorectal cancer patients. Clin Cancer Res (2001) 2.53
Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res (2013) 2.50
Use of research biopsies in clinical trials: are risks and benefits adequately discussed? J Clin Oncol (2012) 2.43
Low correspondence between K-ras mutations in pancreatic cancer tissue and detection of K-ras mutations in circulating DNA. Pancreas (2006) 2.31
Therapeutic advances in pancreatic cancer. Gastroenterology (2013) 2.17
Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res (2008) 2.16
Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat Med (2014) 2.12
KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene (2006) 2.07
Unique localization of circulating tumor cells in patients with hepatic metastases. J Clin Oncol (2009) 1.99
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun (2015) 1.94
EMT, CTCs and CSCs in tumor relapse and drug-resistance. Oncotarget (2015) 1.92
Detection of circulating pancreas epithelial cells in patients with pancreatic cystic lesions. Gastroenterology (2013) 1.92
KRAS: feeding pancreatic cancer proliferation. Trends Biochem Sci (2014) 1.85
Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial. Ann Oncol (2013) 1.82
Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem (2014) 1.78
Oncogenic KRAS signalling in pancreatic cancer. Br J Cancer (2014) 1.71
Single-cell RNA sequencing identifies extracellular matrix gene expression by pancreatic circulating tumor cells. Cell Rep (2014) 1.69
Cancer. Circulating tumor cells. Science (2013) 1.68
Multimarker gene analysis of circulating tumor cells in pancreatic cancer patients: a feasibility study. Oncology (2012) 1.68
Pancreatic adenocarcinoma. N Engl J Med (2014) 1.67
Prognostic value of circulating tumor cells in patients with pancreatic cancer: a meta-analysis. Tumour Biol (2013) 1.64
New biomarkers and targets in pancreatic cancer and their application to treatment. Nat Rev Gastroenterol Hepatol (2012) 1.57
K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance. J Clin Oncol (1999) 1.53
A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. Br J Cancer (2011) 1.50
Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res (2000) 1.47
Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses. Clin Cancer Res (2015) 1.45
"Sentinel" circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease. PLoS One (2014) 1.34
Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nat Commun (2015) 1.33
Detection of circulating tumor cells in patients with pancreatic cancer: a preliminary result. J Hepatobiliary Pancreat Surg (2008) 1.33
Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features. Clin Cancer Res (1998) 1.24
Capture, release and culture of circulating tumor cells from pancreatic cancer patients using an enhanced mixing chip. Lab Chip (2013) 1.23
Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother Radiopharm (2001) 1.21
Circulating tumor cells in pancreatic cancer patients: methods of detection and clinical implications. Int J Cancer (2013) 1.20
RAS: target for cancer therapy. Cancer Invest (2008) 1.18
Plakoglobin: role in tumorigenesis and metastasis. Int J Cell Biol (2012) 1.15
Building better monoclonal antibody-based therapeutics. Nat Rev Cancer (2015) 1.15
K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer. Eur J Surg Oncol (2010) 1.15
Cancer statistics: current diagnosis and treatment of pancreatic cancer in Shanghai, China. Cancer Lett (2014) 1.14
Early detection of sporadic pancreatic cancer: summative review. Pancreas (2015) 1.10
Beyond counting tumor cells. Nat Biotechnol (2012) 1.09
Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival. Clin Cancer Res (2002) 1.08
Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility. Clin Cancer Res (2015) 1.03
Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer. Cancer (2015) 1.03
The detection of EpCAM(+) and EpCAM(-) circulating tumor cells. Sci Rep (2015) 1.02
Circulating tumor cells in the diagnosis and management of pancreatic cancer. Biochim Biophys Acta (2012) 1.02
Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov (2015) 1.01
A prospective study of detection of pancreatic carcinoma by combined plasma K-ras mutations and serum CA19-9 analysis. Pancreas (2002) 1.00
Marker expression in circulating cancer cells of pancreatic cancer patients. J Surg Res (2010) 0.98
Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis. PLoS One (2013) 0.96
Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer. Sci Rep (2015) 0.96